Nanthealth LLC (NYSE:NH) shares were up 4.8% during mid-day trading on Tuesday . The stock traded as high as $13.50 and last traded at $13.22, with a volume of 162,779 shares. The stock had previously closed at $12.61.

Several research analysts recently issued reports on NH shares. FBR & Co reissued a “buy” rating on shares of Nanthealth in a research note on Wednesday, August 10th. Cowen and Company started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 price objective on the stock. Canaccord Genuity started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Jefferies Group started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating on the stock. Finally, First Analysis started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

The company’s market capitalization is $1.60 billion. The firm has a 50 day moving average price of $11.44 and a 200-day moving average price of $12.40.

Nanthealth (NYSE:NH) last released its earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.26. The business earned $31.50 million during the quarter, compared to analysts’ expectations of $23.55 million. Nanthealth’s revenue for the quarter was up 166.9% on a year-over-year basis. Equities research analysts forecast that Nanthealth LLC will post ($0.63) EPS for the current year.

In other news, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of Nanthealth stock in a transaction dated Tuesday, June 7th. The shares were purchased at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the transaction, the insider now owns 15,000,000 shares in the company, valued at $210,000,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Patrick Soon-Shiong purchased 357,143 shares of Nanthealth stock in a transaction dated Tuesday, June 7th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.